BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial of Bezisterim in Long COVID
Statistically significant benefits were observed in bezisterim-treated Long COVID patients
in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise
Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population
An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options
Therapeutic Areas
BioVie believes that inflammation is central to the development and progression of Alzheimer’s disease. BioVie’s different approach focuses on our novel molecule, bezisterim, currently being studied in people diagnosed with Alzheimer’s disease, and the hypotheses that selective modulation of inflammation, and the enhancement of energy transfer (insulin sensitivity) in the brain, may be able to improve memory and thinking, and may protect against neurodegeneration.
Parkinson’s disease is a neurodegenerative disorder that affects predominately the dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra. Symptoms, which usually begin gradually and increase over time, can include difficulty walking and talking, mental and behavioral changes, sleep problems, memory difficulties, and fatigue.
Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more. Common symptoms include lingering loss of smell and taste, hearing loss, extreme fatigue, and “brain fog,” though persistent cardiovascular and respiratory problems, muscle weakness, and neurologic issues have also been documented.
We are not only pioneering biotechnological advancements, but also delving deep into the intricacies of our individual genetic codes by measuring DNA methylation, which is an epigenetic mechanism that regulates gene expression by recruiting proteins involved in gene repression or by inhibiting the binding of transcription factor(s) to DNA.
We are at the forefront in the exploration of treatments for ascites, the condition characterized by the excessive accumulation of abdominal fluid. Ascites frequently occurs in cases of advanced liver cirrhosis, which can result from the progression of metabolic dysfunction-associated steatohepatitis (MASH), infection with Hepatitis B & C, alcoholism, and other factors. It’s worth noting that ascites is the most common complication associated with advanced (“decompensated”) liver cirrhosis, and its complications can pose life-threatening risks.
Latest Press Releases
Loading news...
Info for Investors
This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements.
For Forward Looking Statements, click here.
